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Background 
Obstructive Sleep Apnea (OSA) is a respiratory disorder of sleep that is present in over 10% in the middle 
aged population [1-6]. An independent cause of hypertension[7, 8],[9], OSA accelerates the progression of 
existing cardiovascular disease, and increases fatal and non-fatal cardiovascular events [10-12]. OSA worsens 
blood pressure control[13, 14] and increases the risk of coronary disease [15] [16, 17], atherosclerosis[18-20], 
and stroke [21-24]. Impaired endothelial function occur in OSA before clinical manifestation of vascular 
disease [25].  Endothelial dysfunction, the earliest vascular abnormality predicting the development of 
cardiovascular disease in the general population [26-30], occurs in patients with OSA who have not yet 
manifested vascular disease [31-33], and in animal models prior to the appearance of OSA-induced 
hypertension [34]. Increased oxidant production  and decreased anti-oxidant capacity occur in OSA [25]. 
Oxidative stress is essential for the occurrence of endothelial dysfunction in both patients and animal 
models[31, 35-37]. Otherwise, the mechanisms of vascular disease and endothelial dysfunction in OSA remain 
largely unknown.   
 
1- Intermittent hypoxia and cardiovascular disease in OSA:  A patient with OSA experiences recurrent 
episodes of apnea or hypopnea ranging in frequency from 5 to well over 100 events per hour. Each of 
these obstructive respiratory events results in an episode of hypoxia followed by re-oxygenation after 
the termination of the episode. In turn, each episode of hypoxia stimulates the carotid 
chemoreceptors[38] resulting in sympathetic nerve activation [6, 39] and a secondary surge in blood 
pressure[5]. The recurrence of these respiratory events and their respective recovery phases produces 
a characteristic pattern of nocturnal intermittent hypoxia that is unique to OSA. As a result, patients 
with OSA spend their sleep period in a state of intermittent hypoxia and a cycling pattern of recurrent 
surges of vasoconstriction. Significant experimental evidence indicates that intermittent hypoxia is a 
distinct pathophysiological state with a profile of biological consequences that is different from other 
types of hypoxia exposure [40-43]. A memory effect (plasticity) carries over the sympathetic activation 
and vasoconstriction into the daytime [44] in patients with OSA. This plasticity was shown recently to 
be mediated by reactive oxygen species dependent pathway [40]. Thus, the nocturnal intermittent 
hypoxia pattern of OSA mediates the vascular response to apnea [7] [1-6, 45], and is critical for the 
immediate and long term cardiovascular consequences of OSA[1, 3, 7, 39]. OSA, an established 
cardiovascular disease, is a disorder of intermittent hypoxia, sympathetic activation, and increase 
vasoconstriction [46-48].  
 
2- Endothelial dysfunction is the earliest manifestation of vascular disease in OSA: The pathogenesis of 
vascular disease in OSA remains insufficiently understood. OSA related abnormality in vasoregulation 
involves several vascular beds including cerebral perfusion [34, 49, 50], mesenteric circulation [51], and 
importantly limb vessels [36, 52]. In OSA, it is likely that the repetitive episodes of vasoconstriction, 
shear stress, and sympathetic upregulation will result in long term remodeling in the vascular walls and 
therefore account for such impaired vasomotion. However, impairment in vasoregulatory mechanisms 
occurs in the absence of such remodeling [36, 52]. In fact microcirculatory endothelial cell activation in 
OSA directly triggers pro-atherogenic inflammatory response[19] [53]. Thus, vascular dysregulation in 
OSA includes vasodilatory and vasoconstrictor responses, occurs early in the disease process, and is 
independent from vascular remodeling or hypertension. In particular, this vascular dysregulation of 
OSA appears to originate in the endothelium dependent vasomotion [33, 34, 36, 51, 52, 54]. This OSA 
induced impairment in vasomotion has serious implication for vascular disease and for tissue perfusion 
in patients with OSA.  
Impaired NO mediated endothelial vasodilation is well established in OSA [33] [31]. Ip et al 
demonstrated impaired NO related FMD in conduit arteries (brachial) of OSA patients who were otherwise 
free of clinically known cardiovascular disease. This endothelial dysfunction correlated with the severity of 
OSA as measured by the apnea hypopnea index (AHI), and improved after treatment of OSA [52]. A similar 
correlation between NO-dependent baseline vascular diameter and severity of OSA was also reported in a 
large population based study further supporting a cause-effect relationship [55]. Other studies evaluated 
resistance arterioles and found also impairment in NO related endothelial vasodilation [33]. Circulating levels 
of nitrite/nitrate in patients with OSA were decreased at baseline and improved with treatment with 
CPAP[56].  Studies demonstrated improvement in endothelial dysfunction with anti-oxidants in patients with 
OSA and animal models [31, 35, 36], suggesting a role for oxidative stress in the mechanism of decreased NO 
availability in patients with OSA. This provides parallels to other cardiovascular diseases in which oxidative 
stress induced endothelial dysfunction is important[57],[58]. Endothelial dysfunction and decreased NO 
availability is well established in OSA, and is related to increased oxidative stress.  
 
2.a Nitric Oxide deficiency in OSA: The mechanism of NO mediated endothelial dysfunction in OSA is 
unknown but appears to be related to increased endothelial oxidant production [31]. Increased uptake of NO 
by superoxide forming peroxynitrite, an important pathway in vascular diseases, has not been directly 
evaluated in OSA. There are limited data on the expression or function endothelial NO synthase (eNOS), the 
main enzyme producing NO in the endothelium [37]. Decreased production of NO due to decreased substrate 
availability or dysfunction of eNOS has not yet been evaluated in OSA. Decreased availability of NO in disease 
states can be mediated by any one of several mechanisms, broadly categorized into decreased production, 
increased degradation or both [59-62]. eNOS is constitutively expressed in the endothelial cell and is 
responsible for most of the NO production in the endothelium. Decreased eNOS function may be due to 
decreased expression or inhibition of function.  The decrease in NO bioavailability in OSA cannot be explained 
simply by decreased transcription or translation of eNOS enzyme protein.  eNOS may be normal or increased, 
despite endothelial dysfunction, in many vascular disease states, such as diabetes[63], hypertension[64], and 
heart failure [65]. While, overexpression of eNOS by gene transfer can increase NO activity in the vessel wall, 
constitutive overexpression of eNOS accelerated atherosclerosis in association with increased oxidative stress 
[66]. Overall, it is established that vascular disease occurs in the presence of higher levels of eNOS expression 
[66, 67]. 
2. b. Oxidative stress is a possible mechanism of nitric oxide deficiency in OSA:  Superoxide is the most 
important oxidant in the endothelial cell[68-70], and can be produced by a variety of systems, including, 
xanthine oxidoreductase (XOR), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, Cytochrome 
P450 enzymes, and the arachidonic acid pathway enzymes. Of these, NADPH oxidase plays a major role in 
vascular endothelial cells [68, 71].The role of superoxide in the pathogenesis of vascular disease is well 
described [69, 70]. In the early stage of atherosclerosis, superoxide is produced from NADPH oxidase localized 
in the endothelium [72]. Recently, however, increasing evidence is suggesting that eNOS itself can generate 
superoxide under certain pathophysiological conditions. Electron transfer within the active site becomes 
"uncoupled" from L-arginine oxidation; instead, molecular oxygen is reduced to form superoxide [73, 74].  
Superoxide generation by eNOS has been implicated in a variety of experimental and clinical vascular disease 
states, including diabetes [63, 75], hypertension [76], and atherosclerosis [77].  Superoxide has very high rate 
constant for the reaction with NO producing peroxynitrite[78]. Likewise, the newly formed peroxynitrite has a 
very high rate constant for the reaction with BH4, exceeding that of its reaction with most anti-oxidant 
systems in the endothelial cell [79, 80].   
BH4 is a critical co-factor for eNOS function and structure. The importance of BH4 in the catalytic 
process of L-arginine oxidation and NO synthesis by eNOS is well established [81, 82]. BH4 stabilizes and 
donates electrons to the oxygenase domain of eNOS, as the initial step of L-arginine oxidation [83, 84] . When 
BH4 is limiting, electron transfer from eNOS becomes uncoupled from L-arginine oxidation, and superoxide is 
produced from the oxygenase domain[73]. BH4 is important for the function of eNOS, as well as for its 
physical stabilization [85, 86]. Decreased availability of BH4 results in dissociation between eNOS protein levels 
and NO production, a stoichiometric dysfunction often termed “eNOS uncoupling” [81, 82]. The most common 
reason for decreased BH4 availability is BH4 oxidation to BH2 in cases of abundance of peroxynitrite[87].  
In patients with OSA, treatment with anti-oxidants improved endothelial dysfunction [31, 88]. 
Oxidative stress plays a major role in disorders of endothelial dysfunction and NO bioavailability [89-92]. 
Oxidative stress is critical for the pathophysiology of OSA and provides an important link between OSA and its 
vascular complications.  
OSA is associated with increased oxidant production and decreased anti-oxidant capacity. Recent 
studies demonstrated increased peroxynitrite levels in OSA patients [37, 93]. The role of oxidative stress in 
decreased NO availability in patients with OSA is well established [31, 35]. The source and mechanism of 
increased oxidant production or decreased anti-oxidant capacity in OSA is unknown.  
Impaired vascular regulation of the microcirculation occurs in OSA [33, 34, 36] [94]independent of 
hypertension; itself a disorder of the microcirculation[95, 96]. NO related endothelial dysfunction occurs in 
OSA as the earliest vascular abnormality prior to the manifestation of vascular disease [34, 52]and it results in 
impaired vasodilatory response to hypoxia[49]. We hypothesized that patients with OSA who are free of any 
cardiovascular disease will have early microcirculatory changes that are unique to OSA, and therefore would 
resolve with treatment. Given the role of oxidative stress in the vascular disease of OSA [31, 36], we were 
interested in evaluating the role of endothelial derived oxidants in the microcirculatory NO deficiency.  
Understanding these early oxidant related microcirculatory changes would give insight into the mechanism of 
vascular complications in OSA and its impact on perfusion of peripheral tissue. To achieve these goals, we 
developed several methods of evaluating the early preclinical changes in the resistance microcirculation of 
OSA patients.  
 
Methods 
To address our hypothesis, we performed an observational study in OSA patients and healthy controls. 
 Patients with OSA (n=7) were recruited from the OSU sleep disorders center within 4 weeks of their diagnostic 
polysomnography. OSA was defined by an AHI >15 events per hours of sleep. Healthy controls (n=7) were free 
of sleepiness or risk factors of OSA as defined by negative Berlin questionnaire ® and negative Epworth 
Sleepiness Scale (assess sleepiness).  For patients with OSA and healthy controls the following exclusion 
criteria were met: 1)Hypertension defined by existing treatment  with antihypertensives or any measurement 
of systolic blood pressure (SBP) above 130 mmHg, or diastolic blood pressure (DBP) above 85 mmHg;  
2)Dyslipidemia defined by a value of fasting, or random cholesterol, above 180 or fasting LDL over 140 mg/dl; 
3)patients with diabetes defined as existing diagnosis, hemoglobin A1C >7 or fasting glucose >110 on two 
separate measurements (standard fasting glucose or HbA1C criteria); 4)Coronary artery disease (CAD) defined 
by history of angina, coronary event or  abnormal stress test;  5)Peripheral vascular disease (PVD) defined by 
history of stroke, claudication or abnormal ankle brachial index; and 6)Smoking. None of the female 
participants were concurrently pregnant or had been pregnant within the past six months. 
Studies were conducted between 7-9 AM at the Cardiovascular Clinical and Translational Research 
Organization (CCTRO) in a quiet temperature controlled room with subjects in the fasting state ≥8 hours 
Doppler ultrasound studies were done first, followed by blood draw, and then the subcutaneous biopsy of the 
forearm was performed at the end. Only OSA patients returned after 10-12 weeks of treatment for repeat 
FMD, blood draw, and biopsy. Effective treatment was verified by device download. 
 Endothelial function evaluated by Doppler ultrasound technique and measurements of flow mediated 
dilation (FMD) of the brachial artery as a function of endothelial dependent dilation [89, 97]. The protocol was 
performed according to standard guidelines [97].  Image Acquisition was done by a linear array transducer 
with frequency of 7 MHz, and color spectral Doppler(GE Vivid 7). An external electrocardiogram was used. The 
brachial artery was imaged ≈2-12 cm above the antecubital fossa in the longitudinal plane, and a segment with 
clear anterior and posterior intimal interfaces between the lumen and vessel wall was selected for continuous 
2D gray scale imaging. Images were captured for 2 minutes to obtain baseline reading.  
Flow mediated dilation was assessed by inflating a pediatric sphygmomanometers placed on the 
lower forearm for 5 minutes. The longitudinal image of the artery was recorded continuously from 30 seconds 
before to 2 minutes after cuff deflation. FMD is considered as percent change from baseline after 30 seconds 
of deflation.  Endothelial independent vasodilation was assessed by measuring the dilation in response to a 
single sublingual dose of nitroglycerine (0.4 mg).  All recordings were stored digitally and analyzed by two 
blinded observers with known inter-observer variability using specialized software (GE, Echopac Dimension).  
Repeated measurements were compared for analysis of FMD and NTG administration. The formulas used for 
calculation is as follows:   
Flow mediated dilation, %= ((averaged thirty second diameter post cuff release - averaged baseline diameter)/ 
averaged baseline diameter) X 100. And NTG induced dilation%= ((averaged two minute post NTG 
administration diameter - averaged baseline diameter)/ averaged baseline diameter) X 100. 
The patient’s blood was then drawn by CCTRO personnel, obtaining 30 milliliters of blood.  
Skin punch biopsy techniques were used to obtain a 6 mm diameter and 8mm deep cylindrical 
subcutaneous skin biopsy from the forearms of volunteers. Patients with OSA provided biopsies at baseline 
before treatment and 10-12 weeks after effective CPAP treatment, while healthy controls provided the 
biopsies only once. The biopsy tissue was rinsed in phosphate buffered saline (PBS) and in an RNA free 
solution.  The tissue was then bisected into two 3mm sections. The samples were frozen in Optimal Cutting 
Temperature (OCT)  compound at -80°C until use. One section of the tissue was used for LMPC and rtPCR 
study. The other 3 mm section was used for immunohistochemical analysis 
 
Measurements: 
Quantitative immunohistochemistry staining for peroxynitrite was performed on the subcutaneous biopsy.  
Blocks of the subcutaneous tissue were first cryosectioned into 10 μm sections using a cryostat (Leica, 
Bannockburn, IL) and mounted on Superfrost® plus slides (Fisher Scientific). Staining with anti nitrotyrosine 
polyclonal antibody (Upstate Biotechnology, Lake Placid, NY) was performed using an auto-stainer (Dako 
Scientific, Carpinteria, CA) in the OSU core facility. A positive slide indicating the top level of stain density 
possible for a vessel was created by incubating a vessel in a solution of 1mM sodium nitrite, 1 mM hydrogen 
Figure 1: Peroxynitrite deposit in a microcirculatory of an OSA Patient  
Brown stain indicates nitrated tyrosine residues in microcirculation.  
A. A section of pre treatment tissue stained with anti-nitrotyrosine antibody;  
B. A section of post treatment tissue stained with anti-nitrotyrosine antibody 
peroxide in 100 mM sodium acetate, pH 5.0 before applying the primary stain for peroxynitrite.  A negative 
slide indicating the lower limit possible for a skin biopsy stained for peroxynitrite was created by incubating 
the primary antibody with 10 mM nitrotyrosine in PBS for 1 hour at room temperature and this in place of the 
primary antibody. Figure 1 shows an example of nitrotyrosine stain uptake in the microcirculation of an OSA 
patient.  
 The slides were scanned and the 
subcutaneous vessels were marked by a 
technician who was blinded to origin of the 
slides. The technician digitally dissected 
vessels that were less than 300 μm in 
diameter for all slides. Another blinded 
observer used image analysis software 
(BioImagene, Cupertino California) to 
quantify stain densities in the de-identified 
vessels. The stain density was defined as the amount of total of brown stain present in microvasculature from 
tissue sections compared to the blue counterstain in the tissue.  
The subcutaneous tissue was prepared for laser microdissection and pressure catapulting (LMPC) in 
order to procure HMECs according to the protocol developed by Sen et al [98] with modifications. Frozen 
tissue blocks were cut into 12 μm cryostat sections. Two to three sections were mounted on each RNAZap-
treated thermoplastic (polyethylene napthalate)-covered glass slide (PALM Technologies, Bernreid, Germany) 
and treated with RNALater (Ambion, Austin, TX). The sections were stained with fluorescein-labeled UEA I 
(Vector Labs, Burlingame, CA).  We used the laser microdissection system from PALM Technologies for LMPC. 
Figure 2 shows an arteriole with endothelial cells fluorescently stained that has been selected for RNA 
isolation via LMPC.  
Table-1 Baseline characteristics of patients and controls 
Figure 2: Microcirculatory Endothelial Cell Isolation  
A. In fluorescein-labeled UEA I stained arterioles; localization of 
stain in microcirculatory endothelial cells is performed to 
enable cell selection by laser capture microdissection,  
B. Area selected and marked for capture and RNA isolation for 
creation of cDNA library. 
RNA Isolation from the LMPC samples 
was performed using the PicoPure RNA 
Isolation Kit (Arcturus, Sunnyvale, CA). RNA 
quantity was measured by using the 
NanoDrop system (NanoDrop Technologies, 
Wilmington, DE). The average amount of RNA 
per patient was 4 ng/µl. 
Levels of RNA transcription were 
determined by Reverse Transcription and Quantitative Real-time PCR (rtPCR):  Amplified RNA was reverse 
transcribed into cDNA, using the SuperScript® VILO cDNA Synthesis Kit (Invitrogen, Carlsbad, CA). Reactions 
were done by using random hexamer priming. cDNA standards were used to determine relative quantities and 
to compare dissociation temperatures to partially ensure correct product formation. β-Actin and 18sRNA gene 
expression was measured to correct for differences in extraction efficiency between samples.  We used the 
ΔCt values in analyzing the PCR results correcting to these house-keeping genes. Primers were from 
SuperArray Bioscience Corporation (Fredrick, MD). 
Results  
Characteristics of participants: Table-1 lists the baseline characteristics of patients and controls. There was no 
significant difference in BMI, age, or sex. 
For OSA patients, average CPAP use on 
device download was mean ± (SEM) 5.05 
± 0.83 hours.  Residual AHI was 3.3±0.7 
events/hour.  
Figure 3: Peroxynitrite Deposits in the 
Microvascular Walls of OSA Patients and Controls 
 
Figure 4: Superoxide Dismutase Transcription in 
Microvascular Endothelial Cells of Patients and 
Matched Controls 
 
 Endothelial function: FMD increased in patients after 12 weeks of CPAP treatment from 5.7 ± (0.5) to 7.3 ± (0. 
9) % with a difference of 1.7 ± (0.6) %, p< 0.04.  Patients with OSA had lower FMD at baseline as compared to 
controls 5.7 ± (0.5) % versus 9.7 ± (0.6) % with a difference of 3.8 ± (0.7) %, p<0.001.  After adjustment for 
BMI, age, and gender, the difference between OSA and control remained significant (difference=3.2 ± (1.1), 
p=0.02).  We also explored relationships between change in FMD after treatment with BMI, AHI, and 
compliance, and no clear associations were found.  
Peroxynitrite deposit in the microcirculation:  Tissue was 
available for immunohistochemistry staining on 5 patients 
with OSA and 5 controls. Peroxynitrite stain density in the 
microcirculation decreased with CPAP treatment from 44.0 ± 
(1.6) stain density units (SDU) to 30.50 ± (2.3) SDU with a 
difference of-13.5 ± (2.9) SDU, p=0.009. Microcirculatory 
peroxynitrite stain density was increased in patients with OSA 
compared to controls 44.0 ± (1.6) SDU versus 21.8± (1.9) SDU with a difference of -22.3 ± (2.6) SDU, p<0.001.  
Figure 3 is an individual value line plot showing the peroxynitrite deposit relationship in the microvasculature 
between patients and controls.  We also adjusted for BMI, age, sex for the comparison between patients and 
controls, and the adjusted difference remained significant (difference=-23.1±(6.4), p=0.02). 
Quantitative PCR studies: 
 1- Transcription of  Zinc, copper superoxide dismutase (SOD-
1):   Quantitative PCR measurement of SOD 1 revealed a 
decrease in expression with treatment of OSA from -4.0 to -12.1 
∆Ct with a difference of -8.3 ± (2.1) ∆Ct, p=0.011. Figure 4 is an 
Figure 5: Endothelial Nitric Oxide Transcription 
in Microvascular Endothelial Cells of Patients 
and Matched controls 
individual value line plot showing the relationship between transcription of SOD-1 in patients before and after 
treatment. 
2- Transcription of endothelial nitric oxide synthase (eNOS):   
There was a decrease in eNOS transcription with CPAP 
treatment from 5.2 to -1.3 ∆Ct with a difference of -6.5 ± (2.5) 
∆Ct, p=0.05. Figure 5 provides the individual changes with 
CPAP treatment and controls.  
3- Transcription of inducible nitric oxide synthase (iNOS): 
There was no significant difference change in iNOS RNA with 
CPAP treatment -4.3 ± (5.7) ∆Ct at baseline to 0.6 ± (2.4) ∆Ct post treatment with a difference of -4.8 ± (6.1) 
∆Ct, p=0.46. 
Discussion 
This study is the first direct evaluation of the microcirculation in OSA. We examined the subcutaneous 
vascular tissue from patients with OSA and low cardiovascular risk status. We found increased peroxynitrite 
production in the microvascular walls of OSA patients indicating overproduction of NO and superoxide in the 
endothelial environment. A novel endothelial cell isolation technique[98] enabled real time quantification of 
transcription of critical endothelial genes. The uptake of NO by superoxide explains the decreased NO 
availability and endothelial dysfunction in OSA. Additionally, the upregulation of SOD1 in the MVECs confirms 
oxidant over-production in the endothelium. The finding of upregulated eNOS at baseline in OSA patients 
provides a potential source for the overproduction of NO and superoxide. The findings of this study persisted 
after adjustment to BMI, AHI, age, sex, and hours of CPAP use.   
Previous studies reported that endothelial dysfunction in OSA patients was reversible with 
administration of anti-oxidants[31, 35]. In this study we found direct evidence of increased peroxynitrite 
production in the microcirculation of OSA patients providing an explanation for the role of antioxidants. Only 
one previous study reported increased circulating levels of peroxynitrite but did not localize the abnormality 
to the microcirculation[37]. Oxidative stress has been demonstrated in patients with OSA [25, 99]. Oxidant 
overproduction in OSA may be a manifestation of systemic inflammatory response and increased activated 
circulating leukocytes and oxidative burst[100, 101]This study supports increased oxidant production directly 
in the microcirculatory endothelium of OSA patients.   
Peroxynitrite is the product of NO and superoxide. There are several potential sources for superoxide 
in the endothelium[68-70].  However, increased transcription of eNOS in the endothelial cells of OSA patients 
supports that eNOS may be a source of superoxide overproduction in this setting [64, 73].  Upregulation of 
eNOS occurs in several cardiovascular diseases in the presence of decreased NO availability [63] [64] [65]. 
While overexpression of eNOS by gene transfer can increase NO activity in the vessel wall, constitutive 
overexpression of eNOS is associated with accelerated atherosclerosis and increased oxidative stress [66]. A 
recent study reported decreased eNOS protein in harvested venous endothelial cells of OSA patients [37]. The 
technique we used provides absolute quantification of transcription of eNOS in mainly arteriolar endothelial 
cells. The explanation for the different findings may be related to the method and site of isolation. Our 
findings also support possible functional suppression of eNOS or “uncoupling” of eNOS from critical cofactors 
[73]. Superoxide has very high rate constant for the reaction with NO producing peroxynitrite [78]. In turn, 
peroxynitrite has strong predilection of oxidizing tetrahydrobiopterin [79, 80], a critical eNOS cofactor, 
resulting in eNOS uncoupling and production of superoxide directly. Overall, it is established that vascular 
disease occurs in the presence of eNOS overexpression and superoxide overproduction [64], [66], [67]. 
Superoxide generation by eNOS has been implicated in a variety of experimental and clinical vascular disease 
states, including diabetes [63, 75], hypertension [76], and atherosclerosis [77].  Studies evaluating eNOS 
function and superoxide production in the endothelial cells of OSA patients will be needed to confirm our 
findings. 
The microcirculation and particularly the arterioles are critical for the peripheral vascular resistance in hypertension and 
vascular disease. Our functional studies were done on the brachial artery, a conduit vessel, and the structural and PCR 
studies were done on subcutaneous arterioles. Correlation between endothelial dysfunction in the two beds has been 
confirmed [102, 103].  We did not compare the gene expression between controls and patients at baseline. We planned 
the gene testing to explain the treatment effect on peroxynitrite production in the microcirculation. Once we 
established the difference from controls for clinical variables, we only wanted to show that treatment affected 
mechanistic variables in the hypothesized pathway.  
In this direct examination of the microcirculation, we found evidence of increased oxidant production in the 
microcirculation of OSA patients who are free of cardiovascular disease or risk factors. These microcirculatory changes 
were independent of age, weight, or sex, and were only related to OSA, since they reversed with treatment. The 
presence of peroxynitrite makes it highly likely that superoxide is overproduced directly in the microcirculation of OSA 
patients. This is further supported by the findings of upregulated SOD.  Superoxide is likely to be generated directly in 
the endothelial cell, but this must be verified with direct measurement of superoxide production in the endothelium. 
This study supports that endothelial dysfunction in OSA is not related to decreased transcription of eNOS. This study also 
reports the first direct quantification of critical genetic markers of endothelial function in humans with OSA, providing a 
novel method of further studying vascular disease.   
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